Author:
Barcenas C.H.,Hurvitz S.A.,Di Palma J.A.,Bose R.,Chien A.J.,Iannotti N.,Marx G.,Brufsky A.,Litvak A.,Ibrahim E.,Alvarez R.H.,Ruiz-Borrego M.,Chan N.,Manalo Y.,Kellum A.,Trudeau M.,Thirlwell M.,Garcia Saenz J.,Hunt D.,Bryce R.,McCulloch L.,Rugo H.S.,Tripathy D.,Chan A.,Carcas L.,Castrellon A.,Chan D.,Cheong K.,Choi B.,Coleman M.,Conlin A.,Dichmann R.,Ellison D.,Erickson N.,Gore I.,Hansen V.,Huang D.,Hufnagel D.,Kass F.,Kendall S.D.,Kozloff M.,Lawler W.,Nahum K.D.,Pistilli B.,Reyes E.,Seeger J.,Somer R.,Chiu E. Tan,Thomas G.,Tkaczuk K.,Vaziri I.,Wade J.,Wilkinson M.
Funder
Puma Biotechnology Inc
Miller Medical Communications Ltd
National Institutes of Health
Paul Calabresi Clinical Oncology
National Cancer Institute
National Institutes of Health MD Anderson Cancer